KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Shares Outstanding (2018 - 2025)

Amneal Pharmaceuticals (AMRX) has 5 years of Shares Outstanding data on record, last reported at $152.1 million in Q3 2022.

  • For Q3 2022, Shares Outstanding rose 1.86% year-over-year to $152.1 million; the TTM value through Sep 2022 reached $152.1 million, up 1.86%, while the annual FY2021 figure was $149.4 million, 1.78% down from the prior year.
  • Shares Outstanding reached $152.1 million in Q3 2022 per AMRX's latest filing, roughly flat from $152.1 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $170.9 million in Q2 2019 and bottomed at $12.3 million in Q3 2018.
  • Average Shares Outstanding over 5 years is $136.3 million, with a median of $149.1 million recorded in 2021.
  • The widest YoY moves for Shares Outstanding: up 32.22% in 2019, down 25.17% in 2019.
  • A 5-year view of Shares Outstanding shows it stood at $115.0 million in 2018, then surged by 32.22% to $152.1 million in 2019, then changed by 0.0% to $152.1 million in 2020, then fell by 1.78% to $149.4 million in 2021, then rose by 1.81% to $152.1 million in 2022.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding were $152.1 million in Q3 2022, $152.1 million in Q2 2022, and $152.1 million in Q1 2022.